Ornibel (Ethinylestradiol, Etonogestrel)

Ethinylestradiol is a synthetic estrogen that binds to estrogen receptors in the hypothalamus and pituitary, delivering negative feedback that reduces the secretion of gonadotropins (FSH and LH). This suppression prevents the mid‑cycle LH surge required for ovulation, thereby contributing to the contraceptive effect when combined with a progestin such as etonogestrel.

The dosage regimen for Ornibel is determined by the prescribing healthcare professional. Typically, the vaginal ring is inserted and left in place for a specified period (e.g., three weeks) followed by a ring‑free interval, but the exact schedule and duration are set by the clinician based on individual patient needs and regulatory guidance.

Ornibel is not intended for use during pregnancy; it is a contraceptive method designed to prevent pregnancy. If pregnancy occurs, the product should be discontinued. Regarding breastfeeding, combined hormonal contraceptives are generally not recommended during the early postpartum period, and a healthcare provider should evaluate the risks and benefits before prescribing.

To place an order for Ornibel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and necessary import documentation.

Ornibel delivers its hormones via a vaginal ring, offering continuous low‑dose release and eliminating the need for daily oral dosing, which can improve adherence compared with traditional combined oral contraceptive pills. Efficacy, side‑effect profile, and contraindications are similar to other estrogen‑progestin products, but the delivery system may provide more stable hormone levels and fewer missed‑dose failures.

Ornibel should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposure to extreme heat or freezing conditions. Proper storage helps maintain the integrity of the hormone release mechanism throughout its shelf life.

Ornibel is provided as a flexible vaginal ring that is inserted into the upper vagina by the user or a healthcare professional. Once placed, the ring continuously releases ethinylestradiol and etonogestrel for the prescribed duration (commonly three weeks), after which it is removed and a ring‑free interval follows before a new ring is inserted.

The most serious risks of Ornibel include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, particularly in women with pre‑existing risk factors (e.g., smoking, hypertension, or a history of clotting disorders). Rare hepatic tumors and severe allergic reactions may also occur, requiring immediate medical attention.

Ornibel is contraindicated in women with a history of venous or arterial thromboembolism, known or suspected estrogen‑dependent tumors, uncontrolled hypertension, active liver disease, or migraine with aura. It should also be avoided by smokers over 35 years of age and by individuals with known hypersensitivity to ethinylestradiol, etonogestrel, or any excipients in the ring.